US 11,857,620 B2
Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
Patrick Soon-Shiong, Culver City, CA (US); Peter Sieling, Culver City, CA (US); Kayvan Niazi, Culver City, CA (US); Shahrooz Rabizadeh, Culver City, CA (US); Lise Geissert, Culver City, CA (US); Annie Shin, Culver City, CA (US); Adrian Rice, Culver City, CA (US); Elizabeth Gabitzsch, Culver City, CA (US); Jeffrey Safrit, Culver City, CA (US); and Leonard Sender, Culver City, CA (US)
Assigned to ImmunityBio, Inc., Culver City, CA (US)
Filed by ImmunityBio, Inc., Culver City, CA (US)
Filed on Mar. 10, 2021, as Appl. No. 17/198,164.
Application 17/198,164 is a continuation in part of application No. 17/082,994, filed on Oct. 28, 2020, abandoned.
Application 17/082,994 is a continuation in part of application No. 16/883,263, filed on May 26, 2020, granted, now 11,684,668.
Application 16/883,263 is a continuation in part of application No. 16/880,804, filed on May 21, 2020, abandoned.
Claims priority of provisional application 63/135,380, filed on Jan. 8, 2021.
Claims priority of provisional application 63/121,102, filed on Dec. 3, 2020.
Claims priority of provisional application 63/118,697, filed on Nov. 26, 2020.
Claims priority of provisional application 63/117,922, filed on Nov. 24, 2020.
Claims priority of provisional application 63/117,460, filed on Nov. 24, 2020.
Claims priority of provisional application 63/117,847, filed on Nov. 24, 2020.
Claims priority of provisional application 63/115,127, filed on Nov. 18, 2020.
Claims priority of provisional application 63/082,145, filed on Sep. 23, 2020.
Claims priority of provisional application 63/080,887, filed on Sep. 21, 2020.
Claims priority of provisional application 63/069,598, filed on Aug. 24, 2020.
Claims priority of provisional application 63/067,033, filed on Aug. 18, 2020.
Claims priority of provisional application 63/064,157, filed on Aug. 11, 2020.
Claims priority of provisional application 63/059,975, filed on Aug. 1, 2020.
Claims priority of provisional application 63/053,691, filed on Jul. 19, 2020.
Claims priority of provisional application 63/036,445, filed on Jun. 9, 2020.
Claims priority of provisional application 63/022,146, filed on May 8, 2020.
Claims priority of provisional application 63/016,048, filed on Apr. 27, 2020.
Claims priority of provisional application 63/016,241, filed on Apr. 27, 2020.
Claims priority of provisional application 63/009,960, filed on Apr. 14, 2020.
Claims priority of provisional application 63/010,010, filed on Apr. 14, 2020.
Claims priority of provisional application 62/991,504, filed on Mar. 18, 2020.
Claims priority of provisional application 62/988,328, filed on Mar. 11, 2020.
Prior Publication US 2023/0086390 A1, Mar. 23, 2023
Prior Publication US 2023/0338508 A9, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61K 39/39 (2006.01); C12N 15/86 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 39/39 (2013.01); C12N 15/86 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61P 31/14 (2018.01); C12N 2710/10343 (2013.01); C12N 2770/20022 (2013.01); C12N 2770/20034 (2013.01)] 11 Claims
OG exemplary drawing
 
1. A method of inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in mucosal tissue of a patient, the method comprising administering a vaccine composition to the patient by delivery to nasal mucosa, wherein the vaccine composition comprises a replication defective adenovirus, and wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion, a nucleic acid portion that encodes a SARS-CoV2 S protein, and a nucleic acid portion that encodes a chimeric protein comprising a SARS-CoV2 N protein and an endosomal targeting sequence.